Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Biotechnology

Healthcare
$8.44 +3.04%

+$0.26 today

Market cap
$547.12M
Beta
1.80
P/E (TTM)
-1.7
EPS (TTM)
-$5.11
52W Low $5.37High $17.58

Volume 2.36M

Average 1.24M

DNA Income Before Tax

Profit after all operating and non-operating items but before income tax.

Ginkgo Bioworks Holdings, Inc.NYSE: DNA

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$76.14M, compared with -$90.87M a year earlier. Trailing-twelve-month income before tax was -$298.87M.

Context

  • Income before tax amounted to 184.3% of revenue in FY2025, down 56.8 pp from a year earlier.
  • Income before tax grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$76.14M or moves back toward the trailing-twelve-month quarterly average of -$74.72M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$76.14M+6.5% QoQ
Last fiscal yearDec 2025
-$313.6M+42.7% YoY
LTMMar 2026
-$298.87M+36.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.2%——
1 year+42.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(313.6M) USD
Year-over-year change
+42.7%

Income Before Tax vs competitors

How DNA compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +36.7% is the 3rd highest of 10, against a peer median of -14.0%.
  • Income before tax amounts to 211.5% of revenue for DNA, versus a peer median of 119.6%.
DNA Competitors
Income Before Tax for DNA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGTXMeiraGTx Holdings plcLTM Mar 2026-$120.53M USD+28.0%—151.1%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-$136.49M USD+60.9%—65.4%
VALNValneva SELTM Mar 2026-€137.61M EUR-76.1%—88.0%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026-$145.1M USD-80.3%——
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026-$145.24M USD-14.0%——
ARVNArvinas, Inc.LTM Mar 2026-$221M USD-380.4%—247.2%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-$221.78M USD+44.3%—58.5%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026-$298.87M USD+36.7%—211.5%
REPLReplimune Group, Inc.LTM Dec 2025-$315.82M USD-38.7%——
VIRVir Biotechnology, Inc.LTM Mar 2026-$442.35M USD+23.6%—675.4%
Peer median (excluding DNA) —-14.0%—119.6%

Competitors are the stored peer set for DNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue313.84M477.71M251.46M227.04M170.16M
Cost of Revenue129.69M204.22M54.01M38.55M31.52M
Gross Profit184.15M273.49M197.45M188.49M138.63M
Gross Margin58.7%57.3%78.5%83.0%81.5%
Research & Development1.15B1.05B580.62M424.06M243.77M
Selling, General & Admin862.95M1.43B385.03M246.16M183.29M
Operating Expenses2.01B2.48B1.06B748.25M453.91M
Depreciation & Amortization29.08M61.63M71.55M63.02M58.99M
EBITDA(1.81B)(2.06B)(821.29M)(484.39M)(254.61M)
EBITDA Margin-575.7%-431.2%-326.6%-213.3%-149.6%
Operating Income(1.83B)(2.21B)(864.41M)(559.76M)(315.28M)
Operating Margin-582.6%-462.4%-343.8%-246.5%-185.3%
Interest Income837K20.26M57.22M38.61M22.62M
Interest Expense2.37M106K93K94K0
Other Income / Expenses(9.66M)87.55M(28.53M)12.25M1.68M
Income Before Tax(1.84B)(2.12B)(892.94M)(547.51M)(313.6M)
Pre-Tax Margin-585.7%-444.1%-355.1%-241.1%-184.3%
Income Tax Expense(1.48M)(15.03M)(71K)(479K)(837K)
Net Income(1.83B)(2.1B)(892.87M)(547.03M)(312.76M)
Net Margin-583.1%-440.6%-355.1%-240.9%-183.8%
EPS (Basic)(53.83)(50.15)(18.37)(10.54)(5.64)
EPS (Diluted)(55.53)(50.20)(18.40)(10.54)(5.64)
Weighted Avg Shares32.95M41.93M48.53M51.89M55.46M
Weighted Avg Shares (Diluted)34.01M42M48.61M51.89M55.46M

Ginkgo Bioworks Holdings, Inc.

NYSE:DNA

Intrinsic Alpha fair value

Locked

Current Price

$8.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.